Literature DB >> 18584271

Invasive pneumococcal disease in children in Ireland--the anticipated benefit of conjugate pneumococcal vaccination.

J J Fitzsimons1, A L Chong, M T Cafferkey, K M Butler.   

Abstract

BACKGROUND: Streptococcus pneumoniae is an important cause of childhood illness. Recently a safe and effective 7-valent conjugate pneumococcal vaccine for children has been licensed in the EU. AIMS: To calculate the incidence of invasive pneumococcal disease (IPD) in children in Ireland, to estimate the burden of disease and to anticipate the protective effect of the conjugate vaccine.
METHODS: Retrospective review of data from children with IPD.
RESULTS: Ninety-six cases of IPD in 95 children including two related deaths were identified. All childhood IPD incidence was estimated at 10.6/100,000. We anticipate that the 7-valent conjugate vaccine could prevent up to 90% of sepsis and up to 82.5% of meningitis cases.
CONCLUSIONS: IPD is an important cause of mortality and morbidity in children in Ireland. Routine use of conjugate pneumococcal vaccine would have a significant impact on pneumococcal disease, especially in vaccinated children but also in unvaccinated children and older adults.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18584271     DOI: 10.1007/s11845-008-0167-6

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  28 in total

1.  Potential consequences of the pneumococcal conjugate vaccine.

Authors:  Petros Kopterides; Matthew E Falagas
Journal:  N Engl J Med       Date:  2006-07-06       Impact factor: 91.245

2.  Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I.

Authors:  W P Hausdorff; J Bryant; P R Paradiso; G R Siber
Journal:  Clin Infect Dis       Date:  2000-01       Impact factor: 9.079

3.  The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II.

Authors:  W P Hausdorff; J Bryant; C Kloek; P R Paradiso; G R Siber
Journal:  Clin Infect Dis       Date:  2000-01       Impact factor: 9.079

4.  Post-PCV7 changes in colonizing pneumococcal serotypes in 16 Massachusetts communities, 2001 and 2004.

Authors:  Susan S Huang; Richard Platt; Sheryl L Rifas-Shiman; Stephen I Pelton; Donald Goldmann; Jonathan A Finkelstein
Journal:  Pediatrics       Date:  2005-09       Impact factor: 7.124

5.  Clinical profile of serologically diagnosed pneumococcal pneumonia.

Authors:  T Juvén; J Mertsola; P Toikka; R Virkki; M Leinonen; O Ruuskanen
Journal:  Pediatr Infect Dis J       Date:  2001-11       Impact factor: 2.129

6.  Pneumococcal pneumonia in the UK--how herd immunity affects the cost-effectiveness of 7-valent pneumococcal conjugate vaccine (PCV).

Authors:  E D G McIntosh; P Conway; J Willingham; R Hollingsworth; A Lloyd
Journal:  Vaccine       Date:  2005-02-25       Impact factor: 3.641

7.  Invasive pneumococcal disease in England and Wales: what is the true burden and what is the potential for prevention using 7 valent pneumococcal conjugate vaccine?

Authors:  E D G McIntosh; R Booy
Journal:  Arch Dis Child       Date:  2002-06       Impact factor: 3.791

8.  Pneumococcal disease surveillance in Europe.

Authors:  R G Pebody; W Hellenbrand; F D'Ancona; P Ruutu
Journal:  Euro Surveill       Date:  2006-09

9.  Population-based impact of pneumococcal conjugate vaccine in young children.

Authors:  Katherine A Poehling; Bonnie J Lafleur; Peter G Szilagyi; Kathryn M Edwards; Ed Mitchel; Richard Barth; Benjamin Schwartz; Marie R Griffin
Journal:  Pediatrics       Date:  2004-09       Impact factor: 7.124

10.  Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia.

Authors:  Steven B Black; Henry R Shinefield; Stella Ling; John Hansen; Bruce Fireman; David Spring; Jack Noyes; Edwin Lewis; Paula Ray; Janelle Lee; Jill Hackell
Journal:  Pediatr Infect Dis J       Date:  2002-09       Impact factor: 2.129

View more
  1 in total

1.  Pneumococcal meningitis: clinical outcomes in a pre-vaccine era at a Dublin paediatric hospital, 1999-2007.

Authors:  J M Lucey; P Gavin; M Cafferkey; K M Butler
Journal:  Ir J Med Sci       Date:  2010-11-12       Impact factor: 1.568

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.